{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/osteoporosis-prevention-of-fragility-fractures/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"0562cda5-80f8-5d79-83f3-f1233a8060e3","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 420238e9-4ca2-43fc-ad4f-41c7622a09f0 --><h2>Changes</h2><!-- end field 420238e9-4ca2-43fc-ad4f-41c7622a09f0 -->","summary":null,"htmlStringContent":"<!-- begin item 628a602d-126f-4ba8-be79-2355eccaa1b7 --><!-- begin field d1e627e9-351d-4990-a76b-4043062b940e --><p><strong>May 2020 </strong>— minor update. The section on interpreting fragility fracture risk scores has been updated to clarify the SIGN recommendation that a 10-year fracture risk of 10% is considered to be the threshold for arranging a dual-energy X-ray absorptiometry (DXA) scan in men and women.</p><p><strong>December 2016</strong> — minor update. Information that dosage adjustments of calcium may be required in people with severe kidney disease has been added to the contraindications and cautions section for calcium and colecalciferol preparations [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">ABPI, 2016</a>].</p><p><strong>July 2016</strong> — minor update. The recommendation on alcohol intake in the section on Lifestyle information and advice has been linked to information in the CKS topic on Alcohol - problem drinking, which has been updated in line with the Alcohol Guidelines Review published by the Department of Health (2016).</p><p><strong>December 2015 to January 2016</strong> — reviewed. A literature search was conducted in December 2015 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. The topic has undergone minor restructuring and recommendations have been clarified in line with National Institute for Health and Care Excellence (NICE) guidance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NICE, 2012b</a>]. Recommendations from the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of osteoporosis and the prevention of fragility fractures</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">SIGN, 2015</a>] have been incorporated into this topic.</p><!-- end field d1e627e9-351d-4990-a76b-4043062b940e --><!-- end item 628a602d-126f-4ba8-be79-2355eccaa1b7 -->","topic":{"id":"9f86812a-068c-512b-a1a4-07fda4301d21","topicId":"a4e2c95c-bf7f-4277-b693-c3b2761380ed","topicName":"Osteoporosis - prevention of fragility fractures","slug":"osteoporosis-prevention-of-fragility-fractures","lastRevised":"Last revised in May 2020","chapters":[{"id":"f651cf3f-ec13-5c52-9121-2dd61c54dc3c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"55fa9b49-e88f-5e9b-8156-01352a4c94b5","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a36d9df6-8dba-581c-9361-7b771a120859","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0562cda5-80f8-5d79-83f3-f1233a8060e3","slug":"changes","fullItemName":"Changes"},{"id":"8adeb7b7-191a-5ba3-96f4-d25461c0b901","slug":"update","fullItemName":"Update"}]},{"id":"753ec6fc-9992-587b-870c-2a54cddd30c8","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"62fbf7e5-b097-5a47-af2f-56553c8b16fb","slug":"goals","fullItemName":"Goals"},{"id":"e2d42919-7f54-594f-bcb8-06f2625a550f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"eca5799e-0969-539e-b27e-e8ed22c5cc54","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"355020b6-9455-5e78-8a1a-172fc947a117","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3c308a4e-8074-5dca-a9bd-a56405a0595f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"745ec600-96ff-5056-8ab4-7ebb02e5286d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4541ac61-d9f8-5c7e-a415-a2f3b57c3f45","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"36908082-d612-5f9e-8dd3-09d9bc87bf79","slug":"definition","fullItemName":"Definition"},{"id":"127d59dc-ce73-51b5-80c0-d57209058280","slug":"causes","fullItemName":"Causes"},{"id":"4349db35-6c86-5ebc-a13f-6a1dce22e466","slug":"complications","fullItemName":"Complications"},{"id":"710ee28b-5971-5b43-ac4e-22ac6fba154d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c62b535b-c8d0-5ce1-93bb-867c8644eb2f","slug":"risk-factors","fullItemName":"Risk factors"}]},{"id":"35af4f9e-0536-527c-8b94-94cd5f1fa796","fullItemName":"Management","slug":"management","subChapters":[{"id":"bf661812-0f6f-57a2-b0ab-530b799fc4c4","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"85598d9c-79e5-5925-8dee-46b4cd8f2170","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"f0656a98-39c4-59de-aebb-3eebb0d8dc40","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"38706564-322f-50d2-a7e2-7fe637b76407","slug":"calcium-colecalciferol-vitamin-d3-preparations","fullItemName":"Calcium and colecalciferol (vitamin D3) preparations"},{"id":"0d9951b1-3165-5af5-9601-e12d45a17a6c","slug":"bisphosphonates","fullItemName":"Bisphosphonates"}]},{"id":"c086cbd6-b967-579e-9768-901abfa8d3ca","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"726389ef-f472-5512-a1bf-bf15159602fd","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"f476f450-a081-5a31-a23e-7b837233a18e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"393e0faf-da4e-5bd5-b705-179c32a6c50b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b11023db-83b9-5207-b99c-7917bef26190","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0b683807-10ff-54fc-936a-06d71aa6f8d4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fb240203-2f82-5b14-85ec-55933467aceb","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"782a2ad0-e9ec-5fc2-b2e1-95ec79f6a2f8","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a36d9df6-8dba-581c-9361-7b771a120859","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"93c84f7e-eb39-5dae-9224-ed29207a8d91","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 180c14ae-9b80-4215-974e-a1a1196b3090 --><h3>Previous changes</h3><!-- end field 180c14ae-9b80-4215-974e-a1a1196b3090 -->","summary":null,"htmlStringContent":"<!-- begin item 5cb01006-3228-4044-a7a8-b947d660a655 --><!-- begin field dce71902-edad-4894-a4c1-454aa38d1002 --><p><strong>June 2015</strong> — minor update. Based on an update to the Summary of Product Characteristics for Calcichew D3® chewable tablets, the interaction of calcium salts with zinc and strontium ranelate has been added, and hypersensitivity reactions have been added as possible adverse effects of calcium and vitamin D preparations.</p><p><strong>September 2014</strong> — minor update. Text in the section on NOGG - who to assess has been amended to clarify the NOGG recommendations on when to assess for osteoporotic fracture risk. Text in the section on Drug treatment has been rewritten to clarify when a bisphosphonate should be offered.</p><p><strong>February 2014 </strong>— minor update. Update to the text to reflect the European Medicines Agency's (EMA) recommendations regarding strontium ranelate use, which is restricted to people who cannot be treated with other medicines approved for osteoporosis.</p><p><strong>June to September 2013 </strong>— reviewed. A literature search was conducted in April 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic. The guideline has been extensively re-written to take into account the new method of assessment recommended by the National Institute of Health and Clinical Excellence (NICE) as well as new guidance issued by the National Osteoporotic Guideline Group (NOGG). The guideline also takes into account new recommendations for prescribing vitamin D issued by the Department of Health. Recommendations for Didronel PMO® (a two component drug containing 400 mg of etidronate disodium and 1250 mg of calcium carbonate) have been removed from the topic, following the discontinuation of the product.</p><p><strong>January 2013 </strong>— minor update. Change to the text to reflect updated prescribing advice for strontium ranelate, issued by the Medicines and Healthcare products Regulatory Agency (MHRA) regarding venous thromboembolism and adverse skin reactions.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>March 2012 </strong>— minor update. The 2012/2013 QOF indicators have been added to this topic. Issued in April 2012.</p><p><strong>January 2012 </strong>— minor update. Minor text change clarifying the definition of a T-score reference standard. Issued in January 2012.</p><p><strong>September 2011 </strong>— minor update. A tool to assess if postmenopausal women meet NICE eligibility criteria for DXA scanning and drug treatment to prevent osteoporotic fragility fractures has been removed from the text. In addition a minor typographical error has been corrected. Issued in October 2011.</p><p><strong>June 2011 </strong>— minor update. Prescribing information on atypical stress fractures and oral bisphosphonate treatment replaced. Issued in June 2011.</p><p><strong>May 2011 </strong>— minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>November 2010 to December 2010 </strong>— this is a new CKS topic. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field dce71902-edad-4894-a4c1-454aa38d1002 --><!-- end item 5cb01006-3228-4044-a7a8-b947d660a655 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}